Home » Stocks » Enlivex Therapeutics

Enlivex Therapeutics Ltd. (ENLV)

Stock Price: $13.25 USD 0.60 (4.74%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $13.15 -0.10 (-0.76%) Oct 23, 7:14 PM

Stock Price Chart

Key Info

Market Cap 178.40M
Revenue (ttm) n/a
Net Income (ttm) -9.38M
Shares Out 13.46M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $13.25
Previous Close $12.65
Change ($) 0.60
Change (%) 4.74%
Day's Open 12.67
Day's Range 12.41 - 13.40
Day's Volume 124,875
52-Week Range 3.59 - 16.94

More Stats

Market Cap 178.40M
Enterprise Value 164.89M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.46M
Float 7.60M
EPS (basic) -1.11
EPS (diluted) -0.82
FCF / Share -0.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 25,614
Short Ratio 0.32
Short % of Float 0.34%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.64
Revenue n/a
Operating Income -8.62M
Net Income -9.38M
Free Cash Flow -7.23M
Net Cash 13.51M
Net Cash / Share 1.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -20.19%
ROE -39.92%
ROIC -266.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$22.00*
Low
22.0
Current: $13.25
High
22.0
Target: 22.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-8.62-5.30-2.17-2.82-15.48-7.08-1.15-0.23
Net Income-9.38-4.24-2.50-2.88-15.37-7.02-1.15-0.23
Shares Outstanding8.653.513.433.360.360.310.210.19
Earnings Per Share-1.11-1.40-0.94-1.03-43.20-22.80-5.60-1.20
Operating Cash Flow-7.04-3.16-2.30-2.19-13.25-4.41-0.87-0.15
Capital Expenditures-0.19-0.46-0.13-0.18-0.05-0.06--
Free Cash Flow-7.23-3.62-2.43-2.37-13.30-4.47-0.87-0.15
Cash & Equivalents13.519.789.019.8819.3332.610.27-
Net Cash / Debt13.519.789.019.8819.3332.610.27-
Assets17.5611.039.5410.6320.5232.950.31-
Liabilities6.281.331.051.932.582.280.13-
Book Value11.289.718.498.7017.9330.670.18-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Enlivex Therapeutics Ltd.
Country Israel
Employees 36
CEO Oren Hershkovitz

Stock Information

Ticker Symbol ENLV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ENLV
IPO Date December 12, 1995

Description

Enlivex Therapeutics, a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.